NASDAQ:AUTL Autolus Therapeutics (AUTL) Stock Price, News & Analysis $4.00 -0.44 (-9.90%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$4.00▼$4.5350-Day Range$3.38▼$4.6952-Week Range$2.01▼$7.45Volume1.18 million shsAverage Volume1.45 million shsMarket Capitalization$1.07 billionP/E RatioN/ADividend YieldN/APrice Target$8.70 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Autolus Therapeutics alerts: Email Address Autolus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside117.2% Upside$8.70 Price TargetShort InterestBearish4.67% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.48Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.84) to ($0.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.17 out of 5 starsMedical Sector496th out of 910 stocksBiological Products, Except Diagnostic Industry74th out of 155 stocks 3.4 Analyst's Opinion Consensus RatingAutolus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAutolus Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Autolus Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted4.67% of the outstanding shares of Autolus Therapeutics have been sold short.Short Interest Ratio / Days to CoverAutolus Therapeutics has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldAutolus Therapeutics does not currently pay a dividend.Dividend GrowthAutolus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AUTL. Previous Next 2.5 News and Social Media Coverage News SentimentAutolus Therapeutics has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Autolus Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for AUTL on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows2 people have added Autolus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Autolus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders25.70% of the stock of Autolus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.83% of the stock of Autolus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Autolus Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Autolus Therapeutics are expected to grow in the coming year, from ($0.84) to ($0.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Autolus Therapeutics is -3.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Autolus Therapeutics is -3.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAutolus Therapeutics has a P/B Ratio of 2.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Autolus Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Deal MakerThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.Learn more about this much-needed advancement and investment opportunity here. About Autolus Therapeutics Stock (NASDAQ:AUTL)Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Read More AUTL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AUTL Stock News HeadlinesSeptember 6 at 2:12 PM | seekingalpha.comAutolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull CaseSeptember 1, 2024 | msn.comAutolus Therapeutics plc (AUTL): The Best Multibagger Penny Stock of 2025?September 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...August 27, 2024 | finance.yahoo.comAutolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024August 16, 2024 | seekingalpha.comAutolus Therapeutics plc 2024 Q2 - Results - Earnings Call PresentationAugust 10, 2024 | seekingalpha.comAutolus Therapeutics plc (AUTL) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Autolus Therapeutics Amid Strong Commercial Prospects and Solid FinancialsAugust 9, 2024 | markets.businessinsider.comPositive Outlook for Autolus Therapeutics with Upcoming Obe-cel Approvals and Promising Clinical TrialsSeptember 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...August 8, 2024 | finance.yahoo.comAutolus Therapeutics Reports Second Quarter 2024 Financial Results and Business UpdatesAugust 1, 2024 | seekingalpha.comAutolus Therapeutics: Major Inflection Point On The HorizonJuly 26, 2024 | globenewswire.comAutolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024June 14, 2024 | globenewswire.comAutolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) CongressJune 13, 2024 | investorplace.comStocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a BudgetMay 31, 2024 | globenewswire.comAutolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCOMay 25, 2024 | morningstar.comAutolus Therapeutics PLC ADRMay 22, 2024 | uk.investing.comWells Fargo Overweight on Autolus Therapeutics stock citing positive outlookMay 18, 2024 | finance.yahoo.comQ1 2024 Autolus Therapeutics PLC Earnings CallSee More Headlines Receive AUTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AUTL CUSIPN/A CIK1730463 Webwww.autolus.com Phone442038296230FaxN/AEmployees330Year FoundedN/APrice Target and Rating Average Stock Price Target$8.70 High Stock Price Target$11.00 Low Stock Price Target$4.80 Potential Upside/Downside+117.2%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-208,380,000.00 Net MarginsN/A Pretax Margin-2,229.06% Return on Equity-66.76% Return on Assets-36.90% Debt Debt-to-Equity Ratio0.09 Current Ratio18.55 Quick Ratio18.55 Sales & Book Value Annual Sales$10.50 million Price / Sales101.50 Cash FlowN/A Price / Cash FlowN/A Book Value$1.98 per share Price / Book2.02Miscellaneous Outstanding Shares266,036,000Free Float197,665,000Market Cap$1.07 billion OptionableOptionable Beta2.05 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Christian Martin Itin Ph.D. (Age 60)CEO & Director Comp: $2.44MDr. Martin Pule M.D. (Age 52)MBBS, Founder, Senior VP & Chief Scientific Officer Mr. Robert F. Dolski (Age 53)Senior VP & CFO Mr. Christopher Vann (Age 59)Senior VP & COO Mr. David Brochu (Age 68)Senior VP & Chief Technical Officer Mr. Alexander Swan (Age 59)Senior VP & Chief Human Resources Officer Mr. Brent Rice (Age 58)Senior VP, Chief Commercial Officer & Site Head of US Ms. Olivia ManserDirector of Investor RelationsMr. Alex DriggsSenior VP of Legal Affairs & General Counsel and SecretaryDr. Chris Williams (Age 44)Senior VP & Chief Business Development Officer More ExecutivesKey CompetitorsCrinetics PharmaceuticalsNASDAQ:CRNXADMA BiologicsNASDAQ:ADMAArcellxNASDAQ:ACLXTG TherapeuticsNASDAQ:TGTXBiohavenNYSE:BHVNView All CompetitorsInstitutional OwnershipDriehaus Capital Management LLCSold 7,676 shares on 8/16/2024Ownership: 0.251%Armistice Capital LLCBought 1,578,000 shares on 8/15/2024Ownership: 2.349%Affinity Asset Advisors LLCBought 925,000 shares on 8/15/2024Ownership: 1.616%Millennium Management LLCBought 432,503 shares on 8/15/2024Ownership: 0.306%The Manufacturers Life Insurance Company Sold 46,961 shares on 8/15/2024Ownership: 0.062%View All Institutional Transactions AUTL Stock Analysis - Frequently Asked Questions How have AUTL shares performed this year? Autolus Therapeutics' stock was trading at $6.44 at the start of the year. Since then, AUTL shares have decreased by 37.8% and is now trading at $4.0050. View the best growth stocks for 2024 here. How were Autolus Therapeutics' earnings last quarter? Autolus Therapeutics plc (NASDAQ:AUTL) posted its quarterly earnings data on Thursday, August, 8th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.03. When did Autolus Therapeutics IPO? Autolus Therapeutics (AUTL) raised $125 million in an initial public offering on Friday, June 22nd 2018. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers. Who are Autolus Therapeutics' major shareholders? Autolus Therapeutics' top institutional shareholders include Armistice Capital LLC (2.35%), Affinity Asset Advisors LLC (1.62%), Great Point Partners LLC (1.29%) and Bank of New York Mellon Corp (0.95%). How do I buy shares of Autolus Therapeutics? Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Autolus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Autolus Therapeutics investors own include Sorrento Therapeutics (SRNE), CRISPR Therapeutics (CRSP), VBI Vaccines (VBIV), GW Pharmaceuticals (GWPH), ImmunoGen (IMGN), Teva Pharmaceutical Industries (TEVA) and TG Therapeutics (TGTX). This page (NASDAQ:AUTL) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Autolus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.